-
Tytuł:
-
Disparities in the acceptance of chromosomal microarray at the time of prenatal genetic diagnosis.
-
Autorzy:
-
Swanson K; Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Maternal-Fetal Medicine, University of California, San Francisco, California, USA.; Department of Pediatrics, Division of Medical Genetics, University of California, San Francisco, California, USA.
Loeliger KB; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California, USA.
Chetty SP; Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Maternal-Fetal Medicine, University of California, San Francisco, California, USA.; Fetal Treatment Center, University of California, San Francisco, California, USA.
Sparks TN; Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Maternal-Fetal Medicine, University of California, San Francisco, California, USA.; Fetal Treatment Center, University of California, San Francisco, California, USA.; Institute for Human Genetics, University of California, San Francisco, California, USA.
Norton ME; Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Maternal-Fetal Medicine, University of California, San Francisco, California, USA.; Department of Pediatrics, Division of Medical Genetics, University of California, San Francisco, California, USA.; Fetal Treatment Center, University of California, San Francisco, California, USA.; Institute for Human Genetics, University of California, San Francisco, California, USA.
-
Źródło:
-
Prenatal diagnosis [Prenat Diagn] 2022 May; Vol. 42 (5), pp. 611-616. Date of Electronic Publication: 2022 Feb 08.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Chichester, [Sussex]; New York : Wiley, c1981-
-
MeSH Terms:
-
Amniocentesis*
Prenatal Diagnosis*
Chorionic Villi Sampling ; Chromosome Aberrations ; Female ; Genetic Testing ; Humans ; Microarray Analysis ; Pregnancy ; Retrospective Studies
-
References:
-
BJOG. 2021 Jan;128(2):431-438. (PMID: 32702189)
Clin Ter. 2011;162(5):e141-4. (PMID: 22041812)
Obstet Gynecol. 2016 Dec;128(6):e262-e268. (PMID: 27875474)
Genet Med. 2013 Feb;15(2):139-45. (PMID: 22955112)
J Matern Fetal Neonatal Med. 2014 Sep;27(13):1333-8. (PMID: 24147763)
Prenat Diagn. 2019 Apr;39(5):351-360. (PMID: 30734934)
Eur J Hum Genet. 2019 Feb;27(2):235-243. (PMID: 30297905)
N Engl J Med. 2012 Dec 6;367(23):2175-84. (PMID: 23215555)
J Genet Couns. 2018 Sep;27(5):1130-1147. (PMID: 29516345)
Ultrasound Obstet Gynecol. 2013 Jun;41(6):610-20. (PMID: 23512800)
Prenat Diagn. 2018 Sep;38(10):748-754. (PMID: 29966046)
Best Pract Res Clin Obstet Gynaecol. 2017 Jul;42:53-63. (PMID: 28215395)
Prenat Diagn. 2016 Jul;36(7):656-61. (PMID: 27130707)
Prenat Diagn. 2012 Oct;32(10):976-85. (PMID: 22865506)
-
Grant Information:
-
K12 HD001262 United States HD NICHD NIH HHS; 5K12HD001262-18 United States NH NIH HHS
-
Entry Date(s):
-
Date Created: 20220202 Date Completed: 20220426 Latest Revision: 20230916
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC9116240
-
DOI:
-
10.1002/pd.6109
-
PMID:
-
35106791
-
Objective: Chromosomal microarray (CMA) increases the diagnostic yield of prenatal genetic diagnostic testing but is not universally performed. Our objective was to identify provider and patient characteristics associated with the acceptance of CMA at the time of prenatal genetic diagnostic testing.
Methods: Retrospective cohort study of patients undergoing prenatal genetic diagnostic testing (chorionic villus sampling or amniocentesis) at a single institution between 2014 and 2020. Primary outcome was the acceptance of CMA based on the genetic counselor ,GC who saw the patient. Secondary analyses assessed patient characteristics associated with the acceptance of CMA.
Results: 2372 participants were included. Fifty-eight percent of participants accepted CMA. Acceptance of CMA varied significantly by GC, ranging from 31% to 90%. Patients with public insurance and those who identified as Black or Hispanic/Latina were less likely to have CMA performed (aOR 0.24, 95% CI 0.20-0.30, and 0.68, 95% CI 0.50-0.92). Even among those with a structural anomaly present, public insurance was associated with significantly lower odds of CMA being performed (aOR 0.39, 95% CI 0.25-0.61).
Conclusions: Acceptance of CMA at the time of prenatal genetic diagnostic testing varied based on the GC performing the counseling. Public insurance was associated with lower frequency of accepting CMA.
(© 2022 John Wiley & Sons Ltd.)
